CD137 Protein (Fc Tag)

Produktnummer ABIN7121389

Recombinant CD137-Protein exprimiert in HEK-293 Cells.

Kurzübersicht für CD137 Protein (Fc Tag) (ABIN7121389)

Target: CD137 (TNFRSF9) (Tumor Necrosis Factor Receptor Superfamily, Member 9 (TNFRSF9))

Protein-Typ: Recombinant

Spezies: Hund

Quelle: HEK-293 Cells

Reinheit: >95 % as determined by SDS-PAGE.

Güteklasse: MALS verified

Produktdetails

Aufreinigungstag / Konjugat: Dieses CD137 Protein ist gelabelt mit Fc Tag.

Verwendungszweck: Canine 4-1BB / TNFRSF9 Protein, Fc Tag (MALS verified)

Sequenz: Ile 24 - Ser 185

Produktmerkmale: Canine 4-1BB Protein, Fc Tag (41B-C5253) is expressed from human 293 cells (HEK293). It contains AA Ile 24 - Ser 185 (Accession # XP_850336.1).

Endotoxin-Niveau: Less than 1.0 EU per μg by the LAL method.

Anwendungsinformationen

Applikationshinweise: This protein carries a human IgG1 Fc tag at the C-terminus. The protein has a calculated MW of 43.4 kDa. The protein migrates as 55-65 kDa under reducing (R) condition due to glycosylation.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Buffer: 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH 7.5

Lagerung: -20 °C

Informationen zur Lagerung: -20°C

Antigendetails

Target: CD137 (TNFRSF9) (Tumor Necrosis Factor Receptor Superfamily, Member 9 (TNFRSF9))

Andere Bezeichnung: 4-1BB / TNFRSF9

Hintergrund: Synonyms: TNFRSF9,4-1BB,CD137,CDw137,ILA,
Description: 4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

Molekulargewicht: 43.4 kDa

NCBI Accession: XP_850336

Pathways: Cancer Immune Checkpoints